Adam May on $ABVX's blowout data and subsequent stock crash
YAVP #399
Abivax (ABVX) posted maybe the best ulcerative colitis data anyone's seen, then crashed 60% on a cancer signal Adam May argues is statistical noise. We dig into whether $ABVX is now a mispriced takeout: the maintenance efficacy that beat Rinvoq, how the scary "seven cancer cases" collapse to two, the blackbox question, the Crohn's skew, and the part two safety data due within weeks. Then a quick look at Nectar (NKTR), its alopecia areata data, and the Eli Lilly lawsuit. (Note: you can see Adam’s full update on ABVX here; disclosure: long ABVX and NKTR)
This podcast is sponsored by my upcoming AI webinar with AlphaSense
The AI landscape has never been more crowded — or more confusing. Everyone’s telling you to adopt AI, but almost nobody’s asking the harder question: which tools actually give you an edge?
I’m sitting down with Dave Wang of Wall Street Prompt and Ben Collins of AlphaSense to break down the modern AI stack for investors — from horizontal platforms like OpenAI and Claude to agentic workflows and finance-specific intelligence tools — and where each one actually fits in a real research process.
If you’re trying to build an AI-enabled workflow that sharpens your judgment rather than replacing it, you won’t want to miss this. Join us on June 25th - register now!
Please follow the podcast on Spotify, iTunes, or YouTube! And please be sure to rate / review the podcast if you enjoy it, or share it with someone else who would enjoy it (more listeners is a critical part of the flywheel that keeps this Substack and podcast going!).
Transcript for paid subs begins below (The initial transcript is AI-generated and is replaced with a professionally edited version when available)
Disclaimer: Nothing on this podcast or on this blog is investing or financial advice; please see our full disclaimer here. The transcript below is from a third party transcription service; it’s entirely possible there are some errors in the transcript.
Keep reading with a 7-day free trial
Subscribe to Yet Another Value Blog to keep reading this post and get 7 days of free access to the full post archives.

